The role of cytokines and chemokines in the microenvironment of the blood–brain barrier in leukemia central nervous system metastasis

Mengya Si1
Xiaoyang Jiao2
Yazhen Li2
Huanzhu Chen2
Ping He2
Fang Jiang1

1The First Affiliated Hospital of Shantou University Medical College, 2Cell Biology and Genetics Department, Shantou University Medical College, Shantou, People’s Republic of China

Aim: Central nervous system (CNS) metastasis is a major obstacle in the treatment of leukemia, and the underlying mechanisms of leukemia CNS metastasis are not fully understood. The present study is an investigation of the role of the CNS microenvironment in leukemia CNS metastasis.

Methods: Analog blood–brain barrier (BBB) was set by coculturing human brain microvascular endothelial cells (HBMVECs) and leukemia cells (U937 and IL-60), as well as HBMVECs and sera from leukemia patients, in vitro. The permeability of the HBMVEC monolayer and the levels of tight junction proteins, cytokines and chemokines (C&Ckines) were measured.

Results: The permeability of HBMVECs increased when cocultured with leukemia sera. The expression of C&Ckines was significantly upregulated in HBMVECs cocultured with leukemia sera or leukemia cells, compared to the normal sera (P<0.05, respectively). Specifically, significantly higher levels of vascular endothelial growth factor A (VEGF-A) and matrix metalloprotease 9 (MMP-9) were found in HBMVECs and leukemia cells/sera coculturing systems.

Conclusion: Both leukemia cells and the molecules in leukemia sera play an important role in leukemia CNS metastasis. VEGF-A and MMPs may be the main factors resulting in the degradation of the BBB and inducing the CNS migration of leukemia cells.

Keywords: CNS leukemia, cytokine, chemokine, U937, IL-60

Introduction

Central nervous system (CNS) relapse is the most important complication and obstacle in the treatment of leukemia. Despite extensive efforts, the underlying mechanisms of leukemia CNS metastasis are yet to be fully elucidated. The metastatic cascade includes cancer cell intravasation, circulation, adhesion, and growth in the CNS.1 Although cancer cells may invade the CNS through different pathways, hematogenous seeding plays a significant role in the spreading of cancer cells to the arachnoid mater.2,3 The blood–brain barrier (BBB) is crucial for insulating the CNS microenvironment from the peripheral circulation, efficiently excluding leukocytes, which are otherwise capable of routinely transmigrating across common endothelial layers.4 Brain microvascular endothelial cells (BMVECs) are the main component of the BBB.5 As the first step in CNS leukemia (CNSL), leukemic cells from the bone marrow (BM) migrate toward the brain and bind to the BBB. To overcome the effects of blood flow, leukemic cells adhere to BMVECs for migration.6 After adhesion, leukemia cells disrupt the extracellular matrix (ECM) and the luminal tight junction (TJ) barrier by releasing active biomolecules (cytokines, chemokines, growth factors, and matrix metalloproteases [MMPs]) and then breach the BBB barrier. Finally, to establish CNS foci, leukemia
cells must renew themselves at their new locations. The intricate structure of the BBB makes metastatic extravasation into the brain significantly slower than in other organs, and the process may also require the synergetic input of a panel of molecules.

Molecules involved in tumor metastasis, including cytokines, chemokines, and MMPs, have been extensively studied in leukemia. Chemokines are a family of molecules that govern the homing of leukocytes into different organs, including the CNS. CCL2/monocyte chemoattractant protein-1 (MCP-1) is a dominant chemotactic factor that may offer a specific driving stimulus in response to CCR2-expressing leukocytes that migrate across the BBB. CXCL12 (the ligand for CXCR4) is an important chemokine that attracts and retains leukemia cells within the BM microenvironment. CXCR4 allows the migration and homing of neoplastic cells to sites where stromal cells express CXCL12. MMPs hydrolyze the ECM components in tissues surrounding the tumor, which facilitates the invasion of tumor cells through the basement membrane to distant organs, resulting in metastasis.

In leukemia, MMP-2 and MMP-9 digest the TJs, disrupting the integrity of the luminal aspect of the BBB; therefore, the activity of MMPs is closely correlated with the organ invasiveness of leukemia cells. In addition, MMPs play a synergistic role along with vascular endothelial growth factor (VEGF) in promoting angiogenesis and metastasis. VEGF, a crucial factor in increasing the permeability of the endothelium, has previously been reported to induce disruption of the BBB, culminating in its breakdown. Vascular cell adhesion molecule 1 (VCAM-1) promotes cell adhesion and diapedesis of leukocytes. The interaction of endothelial VCAM-1 with the very late antigen 4 (VLA-4) expressed on leukocytes plays a key role in the transmigration of lymphocytes across the BBB and is implicated in both the capture and strong adhesion of leukocytes to CNS microvessels. Previous in vivo studies revealed strong, positive associations between the expression of cytokines and chemokines (C&CKines) and the development of CNSL. Moreover, C&CKines in the CNS microenvironment might offer more insight into the status of CNSL, compared to those in serum. However, the underlying mechanisms of how C&CKines affect metastasis are unclear.

Both leukemia cells and BMVECs could secrete C&CKines in autocrine or paracrine loops, when leukemia cells traverse the BBB. Circulating C&CKine levels may be determined by the degradation of the BMVECs or the consumption during leukocyte transmigration from BM, as well as across the BBB. In this study, to mimic leukemia metastasis to the CNS, a human BMVECs (HBMVECs) culture system was developed in vitro. Subsequently, we attempted to determine whether sera from leukemia patients or leukemic cells in the CNS microenvironment affect the integrity of BMVECs, through the release of abundant C&CKines into the CNS microenvironment.

**Methods**

This study was approved by the ethics committee of Shantou University Medical College. Written informed consent was obtained from all patients.

**Cell culture and treatment**

Leukemia sera were collected from patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), respectively. Detailed patient information is presented in Table 1. Normal sera were collected from four healthy individuals. Sera were inactivated by heating for 30 min, at 56°C, before use. HBMVECs (ScienCell Research Laboratories, Shanghai, People’s Republic of China) were cultured in 24-well tissue culture inserts and 24-well plates from Corning Incorporated (Corning, NY, USA). BMVECs were grown in ECM media (ScienCell Research Laboratories) containing a low concentration of fetal bovine serum (FBS) (5%), in a humidified atmosphere of 5% CO2/air. The cells were seeded in 24-well plates with Transwell inserts, at 6 × 10^4 cells/cm². When the cell density surpassed 80%, the basic medium was replaced with Dulbecco’s Modified Eagle Medium (DMEM; ScienCell Research Laboratories), with different ratios of sera (30% AML sera, 30% mixed ALL sera, and 30% sera from healthy people).

**Vascular permeability assay**

A total of 6 × 10^6 of HBMVECs were grown onto 24-well tissue culture inserts (Greiner Bio-One GmbH [Kremsmünster, Austria], transparent polyethylene terephthalate [PET] membrane, 0.4 μm pore size, and 4.0 × 10^6 pores/cm²) and incubated at 37°C (5% CO2) in the upper and lower chambers. Paracellular permeability was assessed using 0.06% bovine serum albumin (BSA; ScienCell Research Laboratories). The transmittance was measured with 0.06% BSA on days 1, 5, 10, and 15 to determine the permeability of BMVECs.

**Leukemia cells cocultured with BMVECs in vitro**

Leukemia cells U937 and HL60 (ScienCell Research Laboratories) were cocultured with HBMVECs, respectively. After reaching confluence, the BMVECs were seeded on...
the upper chamber of a Transwell plate, while leukemia cells were added in the lower chamber, with a density of \(5.0 \times 10^6\) cells/L. Supernatants were collected on days 1, 5, 10, and 15 and stored at \(-80^\circ\)C.

### Immunohistochemistry

HBMVECs were stained with human Zonula occludens-1 (ZO-1) antibody (Thermo Fisher Scientific, Waltham, MA, USA; Dako Denmark A/S, Glostrup, Denmark), according to the kit instructions. Slides were analyzed using Olympus Image Scope Software algorithms for staining intensity and the number of positive cells.

### Cytokine measurement

The concentrations of sVCAM-1, MMP-2, MMP-9, VEGF, CXCL-12, and CCL2 in culture supernatants, sera, and cerebrospinal fluid (CSF) were measured by using the Luminex system on a Bioplex (Bio-Rad Laboratories Inc., Hercules, CA, USA).

### Data analyses

Data were presented as medians, with interquartile ranges. The Kruskal–Wallis \(H\) test, Mann–Whitney \(U\) test, and Wilcoxon Rank-Sum test were used to evaluate the differences statistically significant.

### Results

#### The effect of leukemia sera/cells on HBMVEC permeability

To investigate the effect of leukemia sera on BMVEC permeability, FBS was replaced with leukemia sera in our culture system. HBMVECs cultured in leukemia sera could be sustained longer than those cultured in FBS, and the longest survival time was \(~15\) days (Figure 1), indicating that active molecules in leukemia sera may influence HBMVEC survival in vitro.

#### Table I General characteristics of leukemia patients

<table>
<thead>
<tr>
<th>Parameters</th>
<th>AML</th>
<th>ALL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (male/female)</td>
<td>2/2</td>
<td>2/2</td>
</tr>
<tr>
<td>Age (years)</td>
<td>31.00 (22.00–50.50)</td>
<td>33.00 (14.00–45.00)</td>
</tr>
<tr>
<td>WBC(_{\text{Bleu}}) (10E+9/L)</td>
<td>4.40 (2.52–5.24)</td>
<td>1.83 (0.51–7.92)</td>
</tr>
<tr>
<td>Hb(_{\text{Bleu}}) (g/L)</td>
<td>96.50 (73.75–120.00)</td>
<td>111.50 (104.75–121.25)</td>
</tr>
<tr>
<td>PLT(_{\text{Bleu}}) (10E+9/L)</td>
<td>273.50 (90.25–376.50)</td>
<td>152.00 (76.25–312.50)</td>
</tr>
<tr>
<td>WBC(_{\text{CSF}}) (10E+6/L)</td>
<td>6.00 (3.00–13.50)</td>
<td>6.00 (2.50–11.50)</td>
</tr>
<tr>
<td>BBB value</td>
<td>8.39 (6.50–10.80)</td>
<td>9.90 (7.03–13.18)</td>
</tr>
<tr>
<td>sVCAM-1(_{\text{CSF}}) (pg/mL)</td>
<td>1912.31 (913.69–2536.07)</td>
<td>1534.97 (939.37–2018.74)</td>
</tr>
<tr>
<td>sVCAM-1(_{\text{Serum}}) (ng/mL)</td>
<td>349.95 (226.12–587.45)</td>
<td>169.80 (96.07–266.06)</td>
</tr>
<tr>
<td>MMP-2(_{\text{CSF}}) (pg/mL)</td>
<td>680.96 (541.02–760.00)</td>
<td>939.58 (825.12–1066.96)</td>
</tr>
<tr>
<td>MMP-2(_{\text{Serum}}) (pg/mL)</td>
<td>5363.81 (4320.50–6396.16)</td>
<td>7064.78 (3426.89–8299.59)</td>
</tr>
<tr>
<td>MMP-9(_{\text{CSF}}) (pg/mL)</td>
<td>0.56 (0.51–0.62)</td>
<td>0.57 (0.46–0.65)</td>
</tr>
<tr>
<td>MMP-9(_{\text{Serum}}) (pg/mL)</td>
<td>351.61 (190.44–725.71)</td>
<td>401.90 (184.37–1395.83)</td>
</tr>
<tr>
<td>CXCL12(_{\text{CSF}}) (pg/mL)</td>
<td>318.66 (230.13–399.16)</td>
<td>383.14 (290.50–447.28)</td>
</tr>
<tr>
<td>CXCL12(_{\text{Serum}}) (pg/mL)</td>
<td>435.15 (397.11–514.08)</td>
<td>520.56 (362.34–823.28)</td>
</tr>
<tr>
<td>CCL2(_{\text{CSF}}) (pg/mL)</td>
<td>167.22 (86.48–268.20)</td>
<td>778.84 (451.29–996.19)</td>
</tr>
<tr>
<td>CCL2(_{\text{Serum}}) (pg/mL)</td>
<td>35.73 (32.27–63.83)</td>
<td>58.96 (38.93–241.03)</td>
</tr>
<tr>
<td>VEGF-A(_{\text{CSF}}) (pg/mL)</td>
<td>127.90 (65.89–133.93)</td>
<td>95.31 (79.63–152.82)</td>
</tr>
<tr>
<td>VEGF-A(_{\text{Serum}}) (pg/mL)</td>
<td>407.12 (272.38–542.58)</td>
<td>597.48 (388.16–1259.95)</td>
</tr>
</tbody>
</table>

**Note:**\(^*\) \(P<0.05\) when the ALL group is compared with the AML group. Data shown as \(n\) (IQR).

**Abbreviations:** ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CSF, cerebrospinal fluid; WBC, white blood cell; Hb, hemoglobin; PLT, platelet; WBC\(_{\text{CSF}}\), WBC in CSF; IQR, inter-quartile range.
The baseline permeability was 10%, with HBMVEC permeability increasing to static baselines; on day 5, the permeability reached 30% for the ALL sera group and 40% for the AML sera group vs 20% for the control group. From day 10, the permeability increased sharply in the leukemia sera groups. From day 10 to day 15, the permeability was significantly higher in both the AML and ALL groups than in the control group. Specifically, HBMVECs cultured in AML sera had significantly higher permeability (Figure 2).

In the BMVECs and leukemia cells coculture, the permeability increased from day 5 to day 10; however, permeability decreased from day 10 to day 15, which may be caused by the over proliferation of leukemia cells, covering the Transwell membrane filter (Figure 2).

**The effect of leukemia sera on C&Ckines production by HBMVECs**

The expression levels of sVCAM-1, CCL2, and VEGF-A were significantly increased when HBMVECs were cultured in leukemia sera, compared to those measured in normal sera \( (P<0.05) \). Specifically, the concentrations of sVCAM-1, CCL2, MMP-9, and VEGF-A produced by HBMVECs cultured in AML sera were significantly higher than those cultured in ALL sera \( (P<0.05) \). Contrary to MMP-9, the expression of MMP-2 was significantly higher in BMVECs cultured in ALL sera than in sera of AML patients and healthy controls \( (P<0.05) \). There was no statistically significant difference in the expression of CXCL12 among the three groups \( (P>0.05) \) (Table 2 and Figure 2).

**Leukemia cells cocultured with HBMVECs affect the C&Ckines production**

To determine whether leukemia cells interact with the HBMVECs in the CNS microenvironment, we cocultured HBMVECs with U937 (lymphoid cell line) and HL60 (myeloid cell line). The baseline levels of C&Ckines in coculture supernatant were undetectable or very low. After coculturing with leukemia cells, higher CXCL12 and sVCAM-1 levels were observed in U937 cells, whereas higher MMP-2, MMP-9, VEGF-A, and CCL2 levels were found in HL-60 cells (Table 3). All C&Ckines levels were much lower in sole HBMVECs than those in the cocultured groups (Figure 2). For example, the highest level of VEGF-A was detected in the HL60 cocultured system. The production of VEGF-A was 48.89-fold and that of MMP-9 was 88.4-fold higher than in the leukemia sera. In the U937 cocultured system, the production of VEGF was 35.94-fold and that of MMP-9 was 77.3-fold higher than in the ALL sera (Tables 2 and 3). Our data demonstrate that leukemia cells are more potent in activating the production of MMP-9 and VEGF-A by HBMVECs, compared to leukemia sera. In addition, upon comparing the myeloid and lymphoid cell lines, the former seem to have more strength in inducing higher levels of VEGF-A and MMP-9 (Table 3).

**TJ proteins in the cocultured systems**

To further analyze whether higher production of VEGF-A and MMP-9 affects the integrity of the BBB by disrupting the TJs of HBMVEC, fluorescence staining of TJs was performed. The results show that the expression of ZO-1 in HBMVECs decreased after culturing with leukemia cells. ZO-1 (red staining) was restricted to junctional areas and some punctate staining in the cytoplasm (arrows) (Figure 3). Exposure to leukemia cells resulted in a weaker junctional and cytoplasmic pattern of ZO-1 immunoreactivity. Immunohistochemistry showed similar results to those obtained by immunofluorescent staining.

**Discussion**

It is now well established that the tumor microenvironment has a major influence on tumor development, invasion, and metastasis.\(^{27}\) Our data show that BBB integrity relies on the orchestrated role of the C&Ckines secreted by leukemic cells and BMVECs in the BBB microenvironment. The crosstalk and cooperation between BMVECs and leukemia cells are critical for the maintenance of functional barrier integrity,\(^ {28}\) as well as for maintaining the homeostasis of the microenvironment through their constitutive cytokine release.\(^ {29-31}\)

The production of CXCL12, CCL2, and sVCAM-1, which are the important chemokines attracting and retaining leukemia cells from the BM to the CNS, significantly increased when HBMVECs were cocultured with leukemia cells. Higher sVCAM-1 may accelerate circulating leukemic cells to target and adhere to HBMVECs, making the interaction with the endothelium possible, whereas higher CCL2 leads to the formation of new foci in the CNS, enhancing the possibility of white blood cells entering the CNS. Our study reveals that HBMVECs, under the influence of leukemia cells, may be the main source of sVCAM-1 and CCL2 in the CNS, which promote the transfer of leukemia cells to the CNS. Therefore, the levels of C&Ckines in the CNS microenvironment, rather than in serum, are more precise in predicting leukemia CNS metastasis.\(^ {10}\)

The degradation of TJs by MMP-2 and MMP-9 constitutes an important mechanism in the breakdown of the...
Figure 2 (Continued)
BBB, which contributes to the invasion of the CNS in acute leukemia. In our study, leukemia cells activated the HBMVECs to produce significantly higher levels of MMP-2, MMP-9, and VEGF-A, revealing that leukemia cells cross the BBB by stimulating the production of cytokines and then interrupting the ECM and TJs of BMVECs. These results are supported by evidence in vivo, which suggests that higher levels of VEGF-A and MMP-9 in the CSF positively correlate with BBB disruption in patients with CNSL development. Compared with patients without metastasis, CNSL patients had higher levels of MMP-9 and VEGF-A in the CNS. Our results indicate that C&Ckines in the CNS microenvironment may be the main reason for leukemia CNS metastasis.

FBS likely lacks several important characteristics in mimicking the human physiological microenvironment
and, hence, may not be fully adequate for human functional studies, either ex vivo or in vitro. A previous study showed that human and mouse BMVECs cultured in an optimized concentration of growth factors (eg, EGF) gained extended lifetime, as well as good viability and purity. Therefore, we presumed that cells cultured in leukemia sera may be provided with more realistic environmental options to investigate the interactions between the peripheral system and the CNS. In our results, the expression levels of sVCAM-1, MMP-2, and VEGF-A increased after culturing in leukemia sera compared with healthy sera, revealing that bioactive substances in leukemia sera may jointly participate in BBB disruption. Moreover, a positive relationship exists between the concentrations of VEGF-A and MMP-2, MMP-9, and cell permeability, revealing that interactions between BMVECs and cytokines may occur in a dose-dependent manner. If C&Ckines are produced by leukemic cells and BMVECs, through either autocrine or paracrine loops, C&Ckines in the CNS may not be affected by the periphery. This may explain the clinical data suggesting that cytokines in CSF are more potent in influencing BMVECs, than cytokines in serum. C&Ckines produced in the CNS microenvironment may be more potent in recruiting leukemia cells and inducing the breakdown of the BBB. Our study reveals that both leukemia cells and the molecules in leukemia sera play an important role in leukemia CNS metastasis. VEGF-A and MMPs may be the main factors resulting in the degradation of the BBB and inducing the migration of leukemia cells to the CNS.

### Table 2 Cytokines expression in HBMVECs and leukemia sera cocultured system

<table>
<thead>
<tr>
<th>Parameters</th>
<th>AML serum</th>
<th>ALL serum</th>
<th>Control serum</th>
</tr>
</thead>
<tbody>
<tr>
<td>sVCAM-1 (pg/mL)</td>
<td>11.25817 (9150.88–11389.31)</td>
<td>4803.93 (4567.06–9818.30)*</td>
<td>4128.01 (3622.83–8764.46)*</td>
</tr>
<tr>
<td>MMP-2 (pg/mL)</td>
<td>865.82 (821.64–997.75)</td>
<td>1802.72 (1422.30–2072.33)**</td>
<td>860.79 (796.25–1038.08)**</td>
</tr>
<tr>
<td>MMP-9 (pg/mL)</td>
<td>66.72 (50.78–84.86)</td>
<td>16.33 (11.46–19.84)**</td>
<td>479.86 (323.93–602.32)**</td>
</tr>
<tr>
<td>CXCL12 (pg/mL)</td>
<td>397.20 (381.79–403.47)</td>
<td>1328.26 (1261.81–1345.90)</td>
<td>1044.28 (880.23–1170.94)*</td>
</tr>
<tr>
<td>CCL2 (pg/mL)</td>
<td>144.75 (129.08–173.77)</td>
<td>1328.26 (1261.81–1345.90)</td>
<td>1044.28 (880.23–1170.94)*</td>
</tr>
<tr>
<td>MMP-9 (pg/mL)</td>
<td>5894.30 (5124.31–8637.63)</td>
<td>1263.17 (628.28–2876.39)</td>
<td>860.79 (796.25–1038.08)**</td>
</tr>
<tr>
<td>MMP-2 (pg/mL)</td>
<td>200.24 (186.57–369.48)</td>
<td>98.38 (6.25–193.30)#</td>
<td>–</td>
</tr>
<tr>
<td>CXCL12 (pg/mL)</td>
<td>865.82 (821.64–997.75)</td>
<td>1802.72 (1422.30–2072.33)**</td>
<td>860.79 (796.25–1038.08)**</td>
</tr>
<tr>
<td>CCL2 (pg/mL)</td>
<td>397.20 (381.79–403.47)</td>
<td>1328.26 (1261.81–1345.90)</td>
<td>1044.28 (880.23–1170.94)*</td>
</tr>
<tr>
<td>VEGF-A (pg/mL)</td>
<td>144.75 (129.08–173.77)</td>
<td>1328.26 (1261.81–1345.90)</td>
<td>1044.28 (880.23–1170.94)*</td>
</tr>
</tbody>
</table>

### Table 3 Cytokines expression in HL60/U937 and HBMVECs cocultured system

<table>
<thead>
<tr>
<th>Parameters</th>
<th>HL60</th>
<th>U937</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>sVCAM-1 (pg/mL)</td>
<td>854.77 (448.04–931.71)</td>
<td>1286.26 (1136.05–1511.09)**</td>
<td>–</td>
</tr>
<tr>
<td>MMP-2 (pg/mL)</td>
<td>200.24 (186.57–369.48)</td>
<td>98.38 (6.25–193.30)*</td>
<td>–</td>
</tr>
<tr>
<td>MMP-9 (pg/mL)</td>
<td>5894.30 (5124.31–8637.63)</td>
<td>1263.17 (628.28–2876.39)**</td>
<td>–</td>
</tr>
<tr>
<td>CXCL12 (pg/mL)</td>
<td>426.71 (182.01–721.56)</td>
<td>986.23 (378.33–1216.69)</td>
<td>143.32</td>
</tr>
<tr>
<td>CCL2 (pg/mL)</td>
<td>324.21 (167.14–1024.71)</td>
<td>90.52 (9.59–172.61)#</td>
<td>–</td>
</tr>
<tr>
<td>VEGF-A (pg/mL)</td>
<td>7078.21 (5373.40–17453.72)</td>
<td>1263.17 (628.28–2876.39)**</td>
<td>860.79 (796.25–1038.08)**</td>
</tr>
</tbody>
</table>

### Notes
- The concentrations of C&Ckines were measured in the supernatant of HBMVECs and leukemia sera cocultured system. *P<0.05 and **P<0.01 when compared with the AML serum group.
- #P<0.05 and ##P<0.01 when compared with the ALL serum group. Data shown as n (IQR).

### Abbreviations
- ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; C&Ckines, cytokines and chemokines; HBMVECs, human brain microvascular endothelial cells; IQR, inter-quartile range.
Acknowledgment
This study was supported by the Department of Education, Guangdong Government, under the top-tier University Development Scheme for Research and Control of Infectious Diseases.

Disclosure
The authors report no conflicts of interest in this work.

References